Amgen (AMGN) Retained Earnings (2009 - 2026)
Amgen (AMGN) posted quarterly Retained Earnings of -$24.7 billion for Q1 2026, down 10571.0% year-over-year from N/an in Q1 2025, and down 9454.26% quarter-over-quarter from -$258.0 million in Q4 2025.
Amgen (AMGN) Retained Earnings (2009 - 2026) Analysis & Trends
Amgen's Retained Earnings history runs 18 years deep, the most recent figure standing at -$24.7 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 10571.0% year-over-year to -$24.7 billion; the TTM figure through Mar 2026 stood at -$24.7 billion (down 10571.0% YoY), while the FY2025 annual figure was -$258.0 million, up 99.06% from the prior year.
- Retained Earnings for Q1 2026 stood at -$24.7 billion, down from -$258.0 million in the prior quarter.
- The five-year high for Retained Earnings was -$126.0 million in Q3 2023, with the low at -$29.6 billion in Q1 2022.
- The 5-year median for Retained Earnings is -$25.5 billion (2024), against an average of -$16.1 billion.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 99.55% in 2023, then tumbled 20161.9% in 2024.
- Amgen's Retained Earnings stood at -$231.0 million in 2022, then declined by 25.11% to -$289.0 million in 2023, then tumbled by 9446.71% to -$27.6 billion in 2024, then soared by 99.06% to -$258.0 million in 2025, then slumped by 9454.26% to -$24.7 billion in 2026.
- Business Quant data shows AMGN's Retained Earnings at -$24.7 billion in Q1 2026, -$258.0 million in Q4 2025, and -$422.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.28 Bn |
| Mar 31, 2026 | -24.65 Bn |
| Dec 31, 2025 | -258.00 Mn |
| Sep 30, 2025 | -422.00 Mn |
| Jun 30, 2025 | -544.00 Mn |
| Mar 31, 2025 | -231.00 Mn |
| Dec 31, 2024 | -27.59 Bn |
| Sep 30, 2024 | -25.53 Bn |
| Jun 30, 2024 | -27.12 Bn |
| Mar 31, 2024 | -27.87 Bn |
| Dec 31, 2023 | -289.00 Mn |
| Sep 30, 2023 | -126.00 Mn |
| Jun 30, 2023 | -25.54 Bn |
| Mar 31, 2023 | -26.92 Bn |
| Dec 31, 2022 | -231.00 Mn |
| Sep 30, 2022 | -28.07 Bn |
| Jun 30, 2022 | -28.25 Bn |
| Mar 31, 2022 | -29.57 Bn |
| Dec 31, 2021 | -24.60 Bn |
| Sep 30, 2021 | -22.96 Bn |